John G. Harpel

2.6k total citations · 1 hit paper
21 papers, 2.1k citations indexed

About

John G. Harpel is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, John G. Harpel has authored 21 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Hematology and 8 papers in Oncology. Recurrent topics in John G. Harpel's work include Multiple Myeloma Research and Treatments (7 papers), TGF-β signaling in diseases (7 papers) and Protease and Inhibitor Mechanisms (6 papers). John G. Harpel is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), TGF-β signaling in diseases (7 papers) and Protease and Inhibitor Mechanisms (6 papers). John G. Harpel collaborates with scholars based in United States. John G. Harpel's co-authors include Daniel B. Rifkin, Irene Nunes, John S. Munger, Mayumi Abé, Christine N. Metz, David J. Loskutoff, D B Rifkin, Pierre‐Emmanuel Gleizes, Roberta Mazzieri and Filippo G. Giancotti and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

John G. Harpel

21 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

An Assay for Transforming Growth Factor-β Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct

1994 677 citations Mayumi Abé, John G. Harpel et al. Analytical Biochemistry profile →

Peers

Countries citing papers authored by John G. Harpel

Since Specialization

Citations

This map shows the geographic impact of John G. Harpel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John G. Harpel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John G. Harpel more than expected).

Fields of papers citing papers by John G. Harpel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John G. Harpel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John G. Harpel. The network helps show where John G. Harpel may publish in the future.

Co-authorship network of co-authors of John G. Harpel

This figure shows the co-authorship network connecting the top 25 collaborators of John G. Harpel. A scholar is included among the top collaborators of John G. Harpel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John G. Harpel. John G. Harpel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study 2020 ·Blood ·(unknown), John G. Harpel, Sara Miao, Dale L. Ludwig, Mark S. Berger, Gary J. Schiller	2
2	Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma 2008 ·Biology of Blood and Marrow Transplantation ·Tomer M. Mark, Jessica Stern, Jessica Furst, David Jayabalan, Faiza Zafar, (unknown), Roger Pearse, John G. Harpel, Tsiporah B. Shore, Michael W. Schuster, John P. Leonard, Paul J. Christos, Morton Coleman, Rubén Niesvizky	79
3	Effect of bortezomib, cyclophosphamide, and filgrastim on complete remission rates and CD34+ stem cell collections in multiple myeloma (MM) 2008 ·Journal of Clinical Oncology ·Rubén Niesvizky, (unknown), Megan Manco, Tomer M. Mark, Michael W. Schuster, Tsiporah B. Shore, John G. Harpel, Roger Pearse, Faiza Zafar, Mitchell C. Coleman	1
4	Plasminogen/Plasminogen Activator and Growth Factor Activation 2007 ·Novartis Foundation symposium ·Daniel B. Rifkin, Pierre‐Emmanuel Gleizes, John G. Harpel, Irene Nunes, John S. Munger, Roberta Mazzieri, Irene Noguera	8
5	Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant 2007 ·Supportive Care in Cancer ·Michael W. Schuster, Tsiporah B. Shore, John G. Harpel, (unknown), (unknown), (unknown), Robert Gerwien, William F. Hahne, Yuan‐Di C. Halvorsen	14
6	Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma. 2007 ·Blood ·Tomer M. Mark, David Jayabalan, Roger Pearse, Jessica Stern, Jessica Furst, (unknown), John G. Harpel, Tsiporah B. Shore, Michael Schuster, John P. Leonard, Paul J. Christos, Morton Coleman, Rubén Niesvizky	2
7	A Study of a Reduced-Intensity Conditioning Regimen Followed by Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancies Using Campath-1H as Part of a Graft-versus-Host Disease Strategy 2006 ·Biology of Blood and Marrow Transplantation ·Tsiporah B. Shore, John G. Harpel, Michael W. Schuster, Gail J. Roboz, John P. Leonard, Morton Coleman, Eric J. Feldman, Richard T. Silver	9
8	Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens. 2006 ·Blood ·(unknown), Jessica Stern, Michael Schuster, Tsiporah B. Shore, John G. Harpel, Roger Pearse, Faiza Zafar, (unknown), (unknown), David Jayabalan, Selina Chen‐Kiang, Scott Ely, John P. Leonard, Morton Coleman, Rubén Niesvizky	2
9	Bortezomib Added to the Standard Mobilization Regimen of G-CSF and High-Dose Cyclophosphamide Is a Safe and Effective Combination for a High Yield Stem Cell Collection While Promoting Further Tumor Mass Reduction in Myeloma. 2006 ·Blood ·Jessica Stern, (unknown), Michael W. Schuster, Tsiporah B. Shore, John G. Harpel, Roger Pearse, Faiza Zafar, (unknown), (unknown), David Jayabalan, Selina Chen‐Kiang, Scott Ely, John P. Leonard, Morton Coleman, Rubén Niesvizky	3
10	Phase I trial of CG53135-05 to prevent mucositis in patients undergoing high-dose chemotherapy (HDCT) and autologous peripheral blood stem cell transplantation (PBSCT) 2005 ·Biology of Blood and Marrow Transplantation ·Michael W. Schuster, Tsiporah B. Shore, John G. Harpel, (unknown), (unknown), (unknown), Y.-D. Halvorsen, (unknown), William F. Hahne	1
11	BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features. 2005 ·Blood ·Rubén Niesvizky, Karen Pekle, (unknown), Faiza Zafar, S. Ostrow, Roger Pearse, (unknown), (unknown), Scott Ely, Richard Lent, David Jayabalan, Tsiporah B. Shore, John G. Harpel, Michael Schuster, (unknown), Richard R. Furman, John P. Leonard, Selina Chen‐Kiang, Morton Coleman	3
12	Tamoxifen and Estrogen Effects on TGF-β Formation: Role of Thrombospondin-1, αvβ3, and Integrin-Associated Protein 2001 ·Biochemical and Biophysical Research Communications ·John G. Harpel, Stacey Schultz‐Cherry, Joanne E. Murphy-Ullrich, Daniel B. Rifkin	24
13	Interactions between Growth Factors and Integrins: Latent Forms of Transforming Growth Factor-β Are Ligands for the Integrin αvβ1 1998 ·Molecular Biology of the Cell ·John S. Munger, John G. Harpel, Filippo G. Giancotti, Daniel B. Rifkin	196
14	Latent transforming growth factor-β: Structural features and mechanisms of activation 1997 ·Kidney International ·John S. Munger, John G. Harpel, Pierre‐Emmanuel Gleizes, Roberta Mazzieri, Irene Nunes, Daniel B. Rifkin	438
15	TGF‐β Latency: Biological Significance and Mechanisms of Activation 1997 ·Stem Cells ·Pierre‐Emmanuel Gleizes, John S. Munger, Irene Nunes, John G. Harpel, Roberta Mazzieri, Irene Noguera, Daniel B. Rifkin	228
16	An Assay for Transforming Growth Factor-β Using Cells Transfected with a Plasminogen Activator Inhibitor-1 Promoter-Luciferase Construct breakdown → 1994 ·Analytical Biochemistry ·Mayumi Abé, John G. Harpel, Christine N. Metz, Irene Nunes, David J. Loskutoff, D B Rifkin	677
17	TGF-β: Structure, Function, and Formation 1993 ·Thrombosis and Haemostasis ·Daniel B. Rifkin, Soichi Kojima, Mayumi Abé, John G. Harpel	42
18	Role of the latent TGF-beta binding protein in the activation of latent TGF-beta by co-cultures of endothelial and smooth muscle cells. 1993 ·The Journal of Cell Biology ·Robert Flaumenhaft, Mayumi Abé, Yasufumi Sato, Kohei Miyazono, John G. Harpel, Carl‐Henrik Heldin, Daniel B. Rifkin	200
19	TGF-beta: structure, function, and formation. 1993 ·PubMed ·Daniel B. Rifkin, Soichi Kojima, Masahiko Abe, John G. Harpel	50
20	Control of transforming growth factor-β activity: Latency vs. activation 1992 ·PubMed ·John G. Harpel, Christine N. Metz, Soichi Kojima, Daniel B. Rifkin	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact